Table 1.
Relationship between KAI1 expression and clinicopathological factors in breast cancer metastases
| KAI1‐negative | KAI1‐positive | P‐values | |
|---|---|---|---|
| Cases | 62 (67%) | 30 (33%) | |
| Age | P = 0.070 | ||
| <60 years | 31 (60%) | 21 (40%) | |
| ≥60 years | 31 (77%) | 9 (23%) | |
| Metastasis localization | |||
| Liver | 29 (81%) | 7 (19%) | |
| Cerebrum | 19 (54%) | 16 (46%) | |
| Cerebellum | 10 (63%) | 6 (37%) | |
| Meninges | 4 (80%) | 1 (20%) | |
| Estrogen receptor | P = 0.005 | ||
| Negative | 33 (57%) | 25 (43%) | |
| Positive | 29 (85%) | 5 (15%) | |
| Progesterone receptor | P = 0.255 | ||
| Negative | 50 (65%) | 27 (35%) | |
| Positive | 12 (80%) | 3 (20%) | |
| c‐ErbB2 expression | P = 0.657 | ||
| 0, 1+ | 32 (70%) | 14 (30%) | |
| 2+, 3+ | 30 (65%) | 16 (35%) | |
| Ki67 labeling index (LI) | P = 0.067 | ||
| <35 | 45 (74%) | 16 (26%) | |
| ≥35 | 17 (55%) | 14 (45%) | |
χ2‐test.